Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate

PURPOSE: In this study, micron-sized crystalline drug particles of irbesartan (IBS) were prepared to improve its stability and dissolution rate. METHOD: The approach to crystalline particles was based on the liquid precipitation process by which the amorphous particles were prepared. Pharmaceutical acceptable additives were used as the crystallization agent to convert the amorphous drug into crystalline particles. High pressure homogenization (HPH) process has been employed to reduce the size of the crystalline particles, and the micron-sized particles were obtained by the freeze-drying process. RESULTS: Different additives show different influences on the polymorphic form of IBS. Polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) were effective in stabilizing amorphous particles instead of converting amorphous drug into crystalline particles, while poloxamer407 (F127) and tween80 (T80) could convert the amorphous drug into crystalline particles. T80 was also effective in controlling the particle size than that of F127. After HPH, crystalline particles with an average of 0.8 μm were obtained. The freeze-dried micron-sized crystalline particles exhibited significantly enhanced in vitro dissolution rate when compared to the raw drug. SEM, FT-IR, XRD, DSC and dissolution rate studies indicated that the micron-sized particles were stable during 6 months storage. CONCLUSION: The preparation of micron-sized crystalline drug particles is an effective way to improve the stability and dissolution rate of irbesartan.